In the enterprise retail landscape, data is the undisputed engine of growth, strategy, and competitive advantage. Organizations invest billions in systems to ca ...

Microsoft expands Copilot with Agentic AI for enterprise automation, introducing Copilot Cowork that can plan tasks, generate reports, manage meetings, and execute workflows across Microsoft 365.

Companies on this list are wonderful examples of how their products expand the power of KM in changing knowledge environments. They stand out in the KM field, and we applaud their accomplishments. As ...

Carrum Health, the leader in value-based Centers of Excellence for specialty care, today announced an exclusive partnership with Virta Health, the leader in reversing metabolic disease, to offer a ...

North Highland, the leading change and transformation consultancy, has been named a recipient of APQC's 2026 Excellence in Knowledge Management (KM) recognition at the enterprise level. The annual ...

Colorado and several Southern and Midwest states would see the biggest increases in incide ...

Referral software companies are another example of businesses that are unlikely to be heavily disrupted by AI. Their products usually function as execution tools for their customers rather than ...

According to APQC’s 2026 Knowledge Management Priorities and Trends research, only 4% of organizations report reaching the “innovating” stage of KM maturity, where knowledge practices are fully ...

Data strategy competitive advantage depends on a proprietary knowledge base of internal and external data powering predictive models.

Dormant access refers to any account or entitlement that keeps its privileges but shows no sign of use for an extended period. This can be a domain admin ...

Presentations highlight patient preference for sebetralstat, early treatment as the strongest driver of response, and sustained effectiveness with use in clinical trialsFRAMINGHAM, Mass. & SALISBURY, ...

NeOnc has formally notified the FDA that the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial has reached Maximum Tolerated Dose (MTD) at Cohort 5 (810 mg, Days 1–5, 28-day ...